Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 264-120-7 | CAS number: 63393-96-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://chesar.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Remarks:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Oct 2015 - Dec 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
- Remarks:
- OECD TG 422
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- 29 July 2016
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Quaternary ammonium compounds, tri-C8-10-alkylmethyl, chlorides
- EC Number:
- 264-120-7
- EC Name:
- Quaternary ammonium compounds, tri-C8-10-alkylmethyl, chlorides
- Cas Number:
- 63393-96-4
- Molecular formula:
- Unspecified
- IUPAC Name:
- Quaternary ammonium compounds, tri-C8-10-alkylmethyl, chlorides
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Lot/batch No. of test material: 30-043-11
- Purity test date: Apr 01, 2015
- Content: w(Mw =404.16 g/mol) = 82.8 g/100 g
w(Mw = 488.32 g/mol) = 100.0 g/100 g
- Expiry date: 02 Jan 2018
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature
- Stability under test conditions: The stability of test substance in rat diet was demonstrated for a period of 8 days at room temperature. At the beginning (during premating), twice during gestation and once during lactation of the study each 3 samples were taken from the lowest and highest concentration for potential homogeneity analyses. These samples were used as a concentration control at the same time. All measured values for the test substance were in the expected range of the target concentrations (90 - 110%), demonstrating the correctness of the preparations.
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The required quantity of test substance was weighed in a beaker depending on the test group and thoroughly mixed with a small amount of food. Then further amounts of food were added to this premix and thoroughly mixed. Afterwards, further amounts of food, depending on the dose group, were added to this premix in order to obtain the desired concentrations. Mixing of this final mix was carried out for about 3 minutes in a laboratory mixer.
FORM AS APPLIED IN THE TEST (if different from that of starting material): with diet
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Sulzfeld, Germany
- Females (if applicable) nulliparous and non-pregnant: yes
- Animals were free from any clinical signs of disease
- Age at study initiation: 13 - 15 weeks
- Weight at study initiation: males: 334.0 g - 374.2 g; females: 194.3 g - 223.5 g
- Housing: individually during study period (during overnight matings male and female mating partners were housed together; pregnant animals and their litters were housed together until PND 13); grouped (up to 5 animals per sex and cage) during pretreatment
- Diet: ad libitum (from the day of supply to the day before necropsy); ground Kliba maintenance diet mouse-rat “GLP” (supplied by Provimi Kliba SA, Kaiseraugst, Switzerland)
- Water: ad libitum
- Acclimation period: 20 days
DETAILS OF FOOD AND WATER QUALITY: The food used in the study was assayed for chemical and for microbiological contaminants. The drinking water was regularly assayed for chemical contaminants as well as for the presence of (pathogenic) microorganisms. On the basis of the analytical findings the drinking water was found to be suitable. With regard to the analytical findings of chemical and microbiological contaminants and the duration of application, the diet was found to be suitable.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12 / 12
IN-LIFE DATES: From: 06 Oct 2015 To: 02 Dec 2015 (males); 21 and 31 Dec 2015 (females)
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The required quantity of test substance was weighed in a beaker depending on the test group and thoroughly mixed with a small amount of food. Then further amounts of food were added to this premix and thoroughly mixed. Afterwards, further amounts of food, depending on the dose group, were added to this premix in order to obtain the desired concentrations. Mixing of this final mix was carried out for about 3 minutes in a laboratory mixer.
DIET PREPARATION
- Rate of preparation of diet (frequency): not specified; The stability of test substance in rat diet was demonstrated for a period of 8 days at room temperature.
- Mixing appropriate amounts with (Type of food): ground Kliba maintenance diet mouse-rat “GLP” (supplied by Provimi Kliba SA, Kaiseraugst, Switzerland)
- Storage temperature of food: not specified; The stability of test substance in rat diet was demonstrated for a period of 8 days at room temperature. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- At the beginning (during pre-mating), twice during gestation and once during lactation of the study each 3 samples were taken from the lowest and highest concentration for potential homogeneity analyses. These samples were used as a concentration control at the same time. At these time points, one sample from the mid concentration was additionally taken for concentration control analysis. The samples were analyzed via HPLC-MS system with external standard quantification. The analytical investigations of the test substance preparations were carried out in compliance with the Principles of Good Laboratory Practice.
All determined mean concentrations were in the range from 90 % - 110 % of the nominal concentration. - Details on mating procedure:
- - Length of cohabitation: overnight (from about 16.00 h until 06.30 - 09.00 h of the following morning) for a maximum of 2 weeks
- A vaginal smear was prepared after each mating and examined for the presence of sperm.
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy (gestation day (GD) 0)
- After successful mating each pregnant female was caged (how): Pregnant females were provided with nesting material (cellulose wadding) towards the end of gestation. - Duration of treatment / exposure:
- males: 37 days; females: 66 days
The duration of treatment covered a 2-weeks premating period and mating in both sexes (mating pairs were from the same test group), 8 days postmating in males and approximately 4 weeks postmating in one female (pregnant by stain) as well as the entire gestation and approximately 3 weeks of lactation period in females up to one day prior to the day of scheduled sacrifice of the animals. - Frequency of treatment:
- continuously (via diet)
- Duration of test:
- 66 days
Doses / concentrationsopen allclose all
- Dose / conc.:
- 1 000 ppm
- Remarks:
- high-dose level;
for females during lactation: 500 ppm;
= mean intake of approx. 54 mg/kg bw/d (males), approx. 78 mg/kg bw/d (females)
- Dose / conc.:
- 300 ppm
- Remarks:
- mid-dose level;
for females during lactation: 150 ppm;
= mean intake of approx. 17 mg/kg bw/d (males), approx. 23 mg/kg bw/d (females)
- Dose / conc.:
- 100 ppm
- Remarks:
- low-dose group;
for females during lactation: 50 ppm;
= mean intake of approx. 6 mg/kg bw/d (males), approx. 8 mg/kg bw/d (females)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: In a dose finding study male and female rats were treated with the test substance (600 ppm and 1800 ppm) via the diet for a period of 14 days. No effects were observed at 600 ppm. At 1800 ppm treatment-related findings like discolored feces, decreased body weight and decreased food and water consumption occured. In two further studies the test substance was administered via gavage at doses of 10, 50 and 250 mg/kg bw/d. Marked effects in respiratory and gastrointestinal tract, which are typical for irritating substances, up to mortality were observed from a dose of 50 mg/kg bw/d . Thus, an application of the test substance via the diet was chosen for this study.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes (for mortality, for any signs of morbidity, pertinent behavioral changes and signs of overt toxicity, parturition and lactation behavior of the dams)
- Time schedule: at least once daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once prior to the first administration (day 0) and at weekly intervals during the administration period
- Examined parameters: abnormal behavior in handling, fur, skin, posture, salivation, respiration, activity/arousal level, tremors, convulsions, abnormal movements, gait abnormalities, lacrimation, palpebral closure, exophthalmos, assessment of the feces discharged during the examination (appearance/ consistency), assessment of the urine discharged during the examination, pupil size
BODY WEIGHT: Yes
- Time schedule for examinations: once a week at the same time of the day (in the morning) until sacrifice with the following exceptions for the females:
• During the mating period, the females were weighed on the day of positive evidence of sperm (GD 0) and on GD 3, 7, 10, 14, 17 and 20.
• Females with litter were weighed on the day of parturition (PND 1), PNDs 4, 7, 10 and 13.
• Body weight was not determined in females without positive evidence of sperm during the mating and the gestation period and in females without litter during the lactation period.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Time schedule for examinations: once a week with the following exceptions:
• Food consumption was not determined during the mating period.
• Food consumption of the females with evidence of sperm was determined on gestation days (GD) 0 - 3, 3 - 7, 7 - 10, 10 - 14, 14 - 17 and 17 - 20.
• Food consumption of the females which gave birth to a litter was determined on PND 1 - 4, 4 - 7, 7 - 10 and 10 - 13.
- Food consumption was not determined in females without positive evidence of sperm during the mating and the gestation period and in females without litter during the lactation period.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at PND 14
- Anaesthetic used for blood collection: Yes (isoflurane)
- Animals fasted: Yes (about 16 to 20 hours)
- How many animals: the first 5 females with litters (in order of delivery) per group
- Parameters checked in table 1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at PND 14 (females)
- Anaesthetic used for blood collection: Yes (isoflurane)
- Animals fasted: Yes (about 16 to 20 hours)
- How many animals: the first 5 females with litters (in order of delivery) per group
- Parameters checked in table 2 were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes; functional observation battery and motor activity assessment (see "OTHER")
OTHER:
Functional observation battery (FOB):
- A functional observational battery was performed in the first five females with litter per group (in order of delivery) at the end of the administration period starting at about 10.00 h on study day 45.
- The FOB started in a randomized sequence with passive observations without disturbing the animals, followed by removal from the home cage, open field observations in a standard arena and sensorimotor tests as well as reflex tests.
- Examined parameters:
• Home cage observations: posture, tremors, convulsions, abnormal movements, gait, other findings
• Open field observations: behavior on removal from the cage, fur, skin, salivation, nasal discharge, lacrimation, eyes/ pupil size, posture, palpebral closure, respiration, tremors, convulsions, abnormal movements/ stereotypes, gait, activity/ arousal level, feces excreted within 2 minutes (consistency/color), urine excreted within 2 minutes (amount/color), rearing within 2 minutes, other findings
• Sensory motor tests/reflexes: reaction to an object being moved towards the face (approach response), touch sensitivity (touch response), vision (visual placing response), pupillary reflex, pinna reflex, audition (startle response), coordination of movements (righting response), behavior during handling, vocalization, pain perception (tail pinch), grip strength of forelimbs, grip strength of hindlimbs, landing foot-splay test
Motor activity assessment:
- measured from 14:00 h onwards on the same day as the FOB was performed (at the end of the administration period) in the first five surviving females with litter (in order of delivery) per group
- The animals were placed in new clean polycarbonate cages with a small amount of bedding for the duration of the measurement. Eighteen beams were allocated per cage. The number of beam interrupts were counted over 12 intervals for 5 minutes per interval.
Estrous cycle:
- In all parental females, estrous cycle length and normality was evaluated by daily analysis of vaginal smear during a minimum of 2 weeks prior to mating and throughout the pairing period until the female exhibited evidence of copulation. Additionally, on the day of scheduled sacrifice, the estrous status was also determined in all female F0 rats.
- For all females in a pool of up to 50 animals, estrous cycle normality was evaluated before the randomization.
Female reproduction and delivery data
- The pairing partners, the number of mating days until vaginal sperm were detected and gestational status were recorded for F0 females.
Sacrifice and pathology
- All parental animals were sacrificed by decapitation under isoflurane anesthesia. The exsanguinated animals were necropsied and assessed by gross pathology, special attention being given to the reproductive organs.
GROSS PATHOLOGY: see table 3, Organ weights
HISTOPATHOLOGY: see table 3 - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Histopathological assessment of the uterus
- Number of implantations - Fetal examinations:
- no
- Statistics:
- see table 4
- Indices:
- Viability index of pups, Survival index of pups (for detailed formulas see "Any other information on materials and methods")
- Historical control data:
- Historical control data to allow comparison with concurrent controls were provided by the test facility for the following parameters: maternal body weights, estrous cycle, mating data, delivery data, litter data, pup weights, pup necropsy observations, anogenital distance, presence of areolas/nipples, clinical pathology testing
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- - food consumption of the high-dose parental females statistically significantly below the control during the premating days 0 - 7 (about 10%)
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- - Absolute eosinophil counts in females of test groups 1, 2 and 3 (100, 300 and 1000 ppm) lower compared to controls. However, the means in the test groups were within the historical control range, whereas that one of the controls was slightly above this range (absolute eosinophil counts 0.07-0.18 Giga/L).
- Red blood cell (RBC) counts in females of test group 3 (1000 ppm) increased, but the values were within the historical control range (RBC 7.71-8.65 Tera/L). - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- - In females of test group 3 (1000 ppm) increased sodium values. Among the electrolyte levels (sodium, potassium, chloride) sodium was the only altered parameter and therefore its change was regarded as treatment-related, but not adverse.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- - insufficient maternal care during PND 1 - 2 and a complete litter loss on PND 3 of one high-dose female
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- All findings (see Attachment) occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without any relation to treatment.
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- All findings (see Attachment) occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without any relation to treatment. The stages of spermatogenesis in the testes of males of test group 3 (1000 ppm) were comparable to those of the controls.
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
Maternal developmental toxicity
- Number of abortions:
- not examined
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- not examined
- Early or late resorptions:
- not examined
- Dead fetuses:
- not examined
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): no effects observed - Changes in number of pregnant:
- no effects observed
- Other effects:
- no effects observed
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Remarks:
- systemic effects
- Effect level:
- ca. 23 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks:
- = 300 ppm
- Basis for effect level:
- behaviour (functional findings)
- food consumption and compound intake
Results (fetuses)
- Fetal body weight changes:
- not examined
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): effects observed, treatment-related
Field "Description (incidence and severity)" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.DescriptionIncidenceAndSeverityFetalPupBodyWeightChanges): - The mean body weights of the high-dose (1000 ppm) male and female pups and both sexes combined were statistically significantly below the concurrent control values on PND 1 (about 14%, 15% and 14%, respectively), in male pups and both sexes combined on PND 7 (about 15%, respectively) and in male pups on PND 10 (about 13%).
- Mean body weight change of the high-dose (1000 ppm) female pups and both sexes combined was statistically significantly below the concurrent control values during PND 4 - 7 (about 15%, respectively).
- 2 male and 1 female runt in the control, 2 male and 7 female runts in the low-dose group, 1 male and 2 female runts in the mid-dose group, 5 male and 13 female runts in the high-dose group.
- 3 male and 9 female runts in the litter of one high-dose female which had a complete litter loss on PND 3. - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Description (incidence and severity):
- for litter weights see "Fetal/pup body weight changes"
- Changes in postnatal survival:
- effects observed, treatment-related
- Description (incidence and severity):
- - complete litter loss of one high-dose female (1000 ppm) on PND 3 (10 cannibalized and 2 dead pups)
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- no effects observed
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- - Statistically significantly increased percentage (97.2% vers. 6.3% in control) of male pups having areolae on PND 13 in the 1000 ppm group.
Effect levels (fetuses)
open allclose all
- Dose descriptor:
- NOAEL
- Remarks:
- development
- Effect level:
- ca. 23 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks:
- = 300 ppm
- Sex:
- female
- Basis for effect level:
- fetal/pup body weight changes
- Dose descriptor:
- NOAEL
- Remarks:
- development
- Effect level:
- ca. 17 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks:
- = 300 ppm
- Sex:
- male
- Basis for effect level:
- fetal/pup body weight changes
- other: increased number of areolae in male pups at PND 13
Overall developmental toxicity
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 300 ppm
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects occurring together with maternal toxicity effects, but not as a secondary non-specific consequence of maternal toxicity effects
- Dose response relationship:
- yes
Any other information on results incl. tables
Table 5: Summary litter report - dead pups
Sex: Female
Test |
Group 0 |
0/ F ppm |
Test |
Group 1/ F 100 ppm |
Test |
Group 300 |
2/ F ppm |
Test |
Group 3/F 1000ppm |
|
Litters with liveborn pups |
N |
10 |
10 |
9 |
10 |
|||||
Pups delivered |
N |
111 |
110 |
101 |
114 |
|||||
found dead / Dead |
N |
0 |
0 |
1 |
2 |
|||||
|
% |
0.0 |
0.0 |
1.0 |
1.8 |
|||||
stillborn / Dead |
N |
2 |
0 |
1 |
0 |
|||||
|
% |
1.8 |
0.0 |
1.0 |
0.0 |
|||||
Alive / Alive |
N |
109 |
110 |
100 |
114 |
|||||
|
% |
98.2 |
100.0 |
99.0 |
100.0 |
|||||
cannibalized / Dead |
N |
1 |
1 |
0 |
11 |
|||||
|
% |
0.9 |
0.9 |
0.0 |
9.6 |
|||||
sacrificed scheduled / Dead |
N |
79 |
73 |
63 |
69 |
|||||
|
% |
71.2 |
66.4 |
62.4 |
60.5 |
|||||
culled / Dead |
N |
29 |
36 |
36 |
32 |
|||||
|
% |
26.1 |
32.7 |
35.6 |
28.1 |
|||||
Litters not surviving Day 13 |
N |
0 |
0 |
0 |
1 |
|||||
|
% |
0.0 |
0.0 |
0.0 |
10.0 |
Statistic Profile = Wilcoxon with Bonferroni-Holm (one-sided-), Wilcoxon with Bonferroni-Holm (one-sided+), Wilcoxon test (two-sided), Fisher's exact test (one-sided-), Fisher's exact test (one-sided+), * p<=0.05, ** p <=0.01, X = Group excluded from statistics
Table 6: Summary pup report - nipple development
|
Test Group 0/ F 0 ppm |
Test Group 1/ F 100 ppm |
Test Group 2/ F 300 ppm |
Test Group 3/ F 1000 ppm |
|
Nipple development [%] |
Mean |
63.3 x+ |
71.5 |
77.8 |
97.2 ** |
[%] |
S.d. |
30.7 |
42.3 |
44.1 |
8.3 |
day 13 Males |
N |
10 |
10 |
9 |
9 |
Nipple Number |
Mean |
1.8 |
2.0 |
2.6 |
3.5 |
[#] |
S.d. |
1.2 |
1.4 |
1.6 |
0.6 |
day 13 Males |
N |
10 |
10 |
9 |
9 |
Statistic Profile = Wilcoxon with Bonferroni-Holm (one-sided+), * p<=0.05, ** p <=0.01, X = Group excluded from statistics
x=WILCOX
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of the present OECD 422 combined repeated dose toxicity study with the reproductive/developmental screening test in Wistar rats the test substance caused signs of systemic toxicity (decreased food consumption and decreased body weight parameters in male and female parental animals) at a concentration of 1000 ppm in the diet. Thus, the no observed adverse effect level (NOAEL) for general systemic toxicity was 300 ppm for male (about 17 mg/kg bw/d) and female Wistar rats (about 23 mg/kg bw/d).
The NOAEL for fertility and reproductive performance was 1000 ppm for male (about 54 mg/kg bw/d) and female (about 78 mg/kg bw/d) Wistar rats, the highest concentration tested.
The NOAEL for developmental toxicity in the offspring was 300 ppm, based on decreased pup body weights and an increased number of areolae in male pups at PND 13. - Executive summary:
In an OECD 422 study, the test compound was administered daily as a constant homogeneous addition to the food in different concentrations to groups of 10 male and 10 female Wistar rats to screen for potential systemic, reproductive and developmental toxicity. After a two-week premating period, these parental animals were mated and the females were allowed to give birth and bring up the offspring until sacrifice on PND 4 or PND 13.
Analyses confirmed the overall accuracy of the prepared concentrations and the homogeneity of the test substance in the diet. The stability of these preparations was also demonstrated over a period of 8 days under ambient conditions.
In the clinical examinations of the parental animals F0 no clinical symptoms were caused by the test compound up to the high concentration of 1000 ppm. In the subsequent investigations including the detailed clinical observation (DCO), the functional observational battery (FOB) and the measurement of motor activity (MA) no treatment related differences to control were observed at any concentration.
Food consumption of the high-dose F0 males was statistically significantly below the concurrent control values during the entire premating period (up to 11%) and in the high-dose females during premating days 0 - 7 (about 10%).
The mean body weights of the high-dose parental males were statistically significantly below the concurrent control values during the mating and postmating period as well as the terminal body weights. (up to 6%).
Additionally the mean body weight change of the high-dose parental males was statistically significantly below the concurrent control values during premating (up to 38%).
In summary the affected food consumption and body weight parameters of the rats of the high dose group point to systemic toxicity. This trend is only borderline; however, the total of minor changes is considered as an adverse effect of treatment. Concerning clinical pathology no treatment-related, adverse effects were observed up to a concentration of the compound of 1000 ppm in the diet. Regarding pathology all findings occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without any relation to treatment. Regarding fertility and reproductive performance, no signs of toxicity were observed in male or female parental animals of all test groups (100, 300, and 1000 ppm) during the entire study. All F0 parental animals proved to be fertile. Mating behavior, conception, implantation and parturition were not influenced.
Regarding developmental toxicity, the mean body weights of the high-dose (1000 ppm) male and female pups were statistically significantly below the concurrent control values on PND 1. Additionally, lower weights were noted in male pups and both sexes combined on PND 7 (about 15%) as well as in male pups on PND 10 (about 13%). The mean body weight change of the high-dose (1000 ppm) female pups and both sexes combined was statistically significantly below the concurrent control values during PND 4 - 7 (about 15%).
In summary, the decreased pup body weight parameters in the high-dose group are considered as an adverse effect of treatment. One high-dose female (1000 ppm) delivered very small pups (all pups are runts at PND 1) and had a complete litter loss on PND 3 due to an insufficient maternal care. Between PND1 and PND3 ten pups of this high-dose female where cannibalized and two pups died. At necropsy the two died pups had an empty stomach.
In test group 3 (1000 ppm) the number of runts was increased (18 vers. 3 runts in the control group), the viability index indicating pup mortality during lactation (PND 0 - 4) was decreased (89.1% vers. 99.2% in control) and the number of cannibalized/dead pups was increased during PND 1 - 4. Although a complete litter loss as finding (with a low incidence) was present in the historical control data of the facility, a treatment related cause of these changes cannot be excluded.
The percentage (97.2% vers. 63.3% in control) of male pups having areolae on PND 13 was statistically significantly increased in test group 3 (1000 ppm). The percantages of the historical controls range between 0% and 81.7%.
This finding was assessed as an adverse treatment related change.All other findings occurred either individually or were biologically equally distributed over control and treatment groups. They were considered to be incidental or spontaneous in origin and without any relation to treatment.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)